Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald, R., Grunwald, C., Egerland, U.(2013) Bioorg Med Chem Lett 23: 4308-4314
- PubMed: 23806553 
- DOI: https://doi.org/10.1016/j.bmcl.2013.05.099
- Primary Citation of Related Structures:  
4KP6 - PubMed Abstract: 
Expanding on HTS hit 4 afforded a series of [1,3,5]triazine derivatives as novel PDE4 inhibitors. The SAR development and optimization process with the emphasis on ligand efficiency and physicochemical properties led to the discovery of compound 44 as a potent, selective and orally active PDE4 inhibitor.
Organizational Affiliation: 
BioCrea GmbH, Meissner Strasse 191, 01445 Radebeul, Germany. rainer.gewald@telecolumbus.net